Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in CheckMate 141 by prior cetuximab use
Purpose: Cetuximab, which modulates immune responses, may affect the efficacy of
subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior …
subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior …
Nivolumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
RL Ferris, L Licitra, J Fayette, C Even… - CLINICAL CANCER …, 2019 - air.unimi.it
PURPOSE: Cetuximab, which modulates immune responses, may affect the efficacy of
subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior …
subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior …
[PDF][PDF] Nivolumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the 3 Head and Neck: Efficacy and Safety in CheckMate 141 by Prior …
RL Ferris, L Licitra, J Fayette, C Even, SR Haddad10… - core.ac.uk
Purpose: Cetuximab, which modulates immune responses, may affect the efficacy of 115
subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior …
subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior …
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
RL Ferris, L Licitra, J Fayette, C Even… - … : an official journal …, 2019 - pubmed.ncbi.nlm.nih.gov
Purpose Cetuximab, which modulates immune responses, may affect the efficacy of
subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior …
subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior …
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
RL Ferris, L Licitra, J Fayette, C Even… - Clinical Cancer …, 2019 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Purpose:</jats: title>< jats: p>
Cetuximab, which modulates immune responses, may affect the efficacy of subsequent …
Cetuximab, which modulates immune responses, may affect the efficacy of subsequent …
Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in checkmate 141 by prior cetuximab use
RL Ferris, L Licitra, J Fayette… - Clinical Cancer …, 2019 - ohiostate.elsevierpure.com
Purpose: Cetuximab, which modulates immune responses, may affect the efficacy of
subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior …
subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior …
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
RL Ferris, L Licitra, J Fayette, C Even, G Blumenschein… - 2019 - repository.icr.ac.uk
PURPOSE: Cetuximab, which modulates immune responses, may affect the efficacy of
subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior …
subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior …
[HTML][HTML] Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior …
RL Ferris, L Licitra, J Fayette, C Even… - … cancer research: an …, 2019 - ncbi.nlm.nih.gov
Purpose: Cetuximab, which modulates immune responses, may affect the efficacy of
subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior …
subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior …
Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in checkmate 141 by prior cetuximab use
RL Ferris, L Licitra, J Fayette… - Clinical Cancer …, 2019 - mdanderson.elsevierpure.com
Purpose: Cetuximab, which modulates immune responses, may affect the efficacy of
subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior …
subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior …
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
RL Ferris, L Licitra, J Fayette, C Even… - … Cancer Research: an …, 2019 - europepmc.org
Purpose Cetuximab, which modulates immune responses, may affect the efficacy of
subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior …
subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior …